Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07672431 · ClinicalTrials.gov registry record · NA
Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT07672431: Clinical Trial NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT07672431 is a NA study that has not yet begun recruiting, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07672431, a NA study, has not yet begun recruiting, sponsored by Barbara Ann Karmanos Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work better than the standard of care alone. The main questions it aims to answer is: * will the addition of the TheraBionic P1 device to standard of care third line treatment affect progression free and overall survival in these participants
Primary Outcome
PFS is defined as the interval from treatment initiation to the date of disease progression of death from any cause, whichever occurs first. The treating investigator will determine disease progression. PFS6 will be calculated as the proportion of participants who are alive without progression at six months post-treatment initiation.
Interventions
- DEVICE TheraBionic P1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-09 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What is known before NCT07672431 opens enrollment
NCT07672431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which TheraBionic P1 is the first listed.
NCT07672431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07672431 about?
NCT07672431 is a clinical study titled "Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression". The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work b...
What is the current status of trial NCT07672431?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2026-09. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07672431?
The interventions under investigation include: TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT07672431?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07672431's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia